A study to determine the efficacy of amritadya guggulu and haritaki churna in medo roga

“A clinical study to determine the efficacy of Amritadya Guggulu and Haritaki Churna in the management of Medoroga w.s.r to Dyslipidemia . ? - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/11/059698

Enrollment

Registered

2023-11-09

Start date

Unknown

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E782- Mixed hyperlipidemia

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients who present with signs and symptoms of medoroga Patients having serum cholesterol 200 to 300mg/dl, s. Triglycerides 150 to 350 mg/dl, S. LDL 100 to 200 mg/dl, S. VLDL 30 TO 100 mg/dl and S. HDL 20 to 40 mg/dl

Exclusion criteria

Exclusion criteria: Patients having past history of Myocardial infarction, unstable angina, congestive cardiac failure and cerebro vascular accident. Patients having past illness like carcinoma, renal and liver disorders Pregnant females and lactating mother

Design outcomes

Primary

Measure	Time frame
A clinical study to determine the efficacy of Amritadya Guggulu & Haritaki Churna in the management of medoroga w.s.r to DyslipidemiaTimepoint: 8 weeks	—

Secondary

Measure	Time frame
To assess the clinical safety & untoward effects of Amritadya Guggulu & Haritaki Churna in patients of Medoroga w.s.r DyslipidemiaTimepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDr Neha Thakur

Rajiv Gandhi Govt Post Graduate Ayurvedic College and hospital Paprola

Dr.geeti@gmail.com7018817072

Outcome results